ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
5 hedge funds and large institutions have $468K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less capital invested
Capital invested by funds: $701K → $468K (-$233K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$151K |
| 2 |
Morgan Stanley
New York
|
+$11.5K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$5.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$176K |
| 2 |
VF
Virtu Financial
New York
|
-$169K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$30.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $286K | -$16.4K | -1,094 | -5% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $136K | +$151K | +10,082 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $28K | -$30.6K | -2,040 | -49% |
|
|
4
Morgan Stanley
New York
| $13K | +$11.5K | +768 | +343% |
|
|
CG
5
Cutler Group
San Francisco,
California
| $5K | +$5.98K | +399 | New |
|
|
6
Jane Street
New York
| – | -$176K | -13,247 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$169K | -12,754 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$1K | -47 | Closed |
|
ZBIO Hedge Fund Activity: Q2 2019 in Review
5 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q2 2019, worth a combined $468K — down 33% from $701K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ZBIO and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $151K. The largest seller was Jane Street, exiting entirely with an estimated $176K sold.
- 5 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q2 2019, down from 6 in Q1 2019.
- Funds reported $468K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q2 2019, down 33% quarter-over-quarter.
- 2 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q2 2019 and 3 closed out, a net change of -1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q2 2019 was Susquehanna International Group, an estimated $151K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q2 2019 was Jane Street, an estimated $176K sold.
Based on aggregated 13F filings for Q2 2019.